Ginkgo Investor Conference Presentation Deck
Synlogic and Ginkgo partnered to develop SYNB1353, a non-colonizing
bacterial strain, as a living treatment for the rare genetic disease
homocystinuria (HCU) - IND planned for 2022
HCU is a disorder characterized by the accumulation of homocysteine,
an amino acid derived from methionine, in the blood and urine.
Degrading methionine in the GI tract prevents methionine absorption
and conversion to homocysteine in plasma.
Ginkgo used its proprietary codebase and leveraged its metagenomic
databases sourced from bacteria, fungi, animals, plants, and protein
engineering expertise to rationally design, build, and test 1000s of
constructs, informed by nature, to improve the performance of two
critical proteins in the Methionine pathway (MetDC and MetP).
Synlogic has announced that it expects to file an investigational new
drug (IND) application with the FDA for SYNB1353 and begin clinical
development in 2022 - this marks a first for Ginkgo-engineered
materials.
Perreault, Mylène. (2021, Nov). Development of an Investigational
Methionine-consuming Synthetic Biotic Medicine (SYNB1353) for the
Treatment of Homocystinuria. Paper presented at the 14th International
Congress of Inborn Errors of Metabolism, Sydney, Australia.
MetP
Methionine (Met)
metP
Met
met DC
3-MTP
Pto
Proc
Met
003-MTP
YjeH
Plasma Methionine (M)
Plasma Homocysteine (M)
600-
400-
200-
0
30
O
Vehicle
*#
Vehicle
*#
+ EcN
ECN SYNB1353
SYNB1353
*#
0.0 0.5 1.0 2.0 4.0 6.0
Time post methionine administration (hrs)
*#
*#
*#
*#
0.0 0.5 1.0 2.0 4.0 6.0
Time post methionine administration (hrs)
16
Property of Ginkgo Bioworks
J.P. MORGAN HEALTHCARE CONFERENCE 2022View entire presentation